Csenge Advisory Group’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.33M | Sell |
2,646
-41
| -2% | -$19.7K | 0.05% | 267 |
|
|
2026
Q1 | $1.32M | Buy |
2,687
+47
| +2% | +$25.5K | 0.06% | 250 |
|
|
2025
Q4 | $1.53M | Sell |
2,640
-119
| -4% | -$67.3K | 0.07% | 227 |
|
|
2025
Q3 | $1.34M | Sell |
2,759
-464
| -14% | -$216K | 0.06% | 232 |
|
|
2025
Q2 | $1.3M | Sell |
3,223
-202
| -6% | -$84.5K | 0.07% | 224 |
|
|
2025
Q1 | $1.46M | Sell |
3,425
-47
| -1% | -$25.5K | 0.08% | 193 |
|
|
2024
Q4 | $1.81M | Sell |
3,472
-335
| -9% | -$184K | 0.1% | 162 |
|
|
2024
Q3 | $2.27M | Buy |
3,807
+67
| +2% | +$39.7K | 0.12% | 141 |
|
|
2024
Q2 | $2.07M | Buy |
3,740
+194
| +5% | +$111K | 0.12% | 132 |
|
|
2024
Q1 | $2.06M | Buy |
3,546
+158
| +5% | +$88.7K | 0.12% | 142 |
|
|
2023
Q4 | $1.8M | Sell |
3,388
-202
| -6% | -$97.8K | 0.11% | 154 |
|
|
2023
Q3 | $1.82M | Sell |
3,590
-86
| -2% | -$45.8K | 0.12% | 142 |
|
|
2023
Q2 | $1.92M | Buy |
3,676
+164
| +5% | +$88.5K | 0.13% | 127 |
|
|
2023
Q1 | $2.02M | Sell |
3,512
-369
| -10% | -$208K | 0.15% | 127 |
|
|
2022
Q4 | $2.14M | Buy |
3,881
+315
| +9% | +$167K | 0.17% | 114 |
|
|
2022
Q3 | $1.81M | Buy |
3,566
+559
| +19% | +$313K | 0.15% | 127 |
|
|
2022
Q2 | $1.63M | Buy |
3,007
+232
| +8% | +$128K | 0.14% | 146 |
|
|
2022
Q1 | $1.64M | Buy |
2,775
+429
| +18% | +$246K | 0.13% | 142 |
|
|
2021
Q4 | $1.2M | Sell |
2,346
-81
| -3% | -$50.6K | 0.11% | 164 |
|
|
2021
Q3 | $1.39M | Buy |
2,427
+81
| +3% | +$44.5K | 0.12% | 160 |
|
|
2021
Q2 | $1.2M | Buy |
2,346
+1,489
| +174% | +$703K | 0.11% | 164 |
|
|
2021
Q1 | $410K | Sell |
857
-134
| -14% | -$64K | 0.04% | 325 |
|
|
2020
Q4 | $462K | Sell |
991
-227
| -19% | -$106K | 0.06% | 240 |
|
|
2020
Q3 | $543K | Sell |
1,218
-2
| -0.2% | -$826 | 0.07% | 208 |
|
|
2020
Q2 | $442K | Buy |
1,220
+221
| +22% | +$74.1K | 0.06% | 216 |
|
|
2020
Q1 | $283K | Buy |
+999
| New | +$315K | 0.07% | 222 |
|
|
2018
Q4 | – | Sell |
-81
| Closed | -$19K | – | 1366 |
|
|
2018
Q3 | $19K | Sell |
81
-1,482
| -95% | -$341K | 0.01% | 401 |
|
|
2018
Q2 | $332K | Buy |
1,563
+105
| +7% | +$22.3K | 0.12% | 167 |
|
|
2018
Q1 | $301K | Buy |
+1,458
| New | +$306K | 0.1% | 194 |
|
|
2017
Q4 | – | Sell |
-1,064
| Closed | -$201K | – | 284 |
|
|
2017
Q3 | $201K | Buy |
+1,064
| New | +$193K | 0.08% | 241 |
|
Other funds holding TMO
Csenge Advisory Group's TMO Position: Q2 2026 in Review
Csenge Advisory Group reduced its Thermo Fisher Scientific (TMO) stake by 1.5% in Q2 2026, selling an estimated $19.7K and leaving 2,646 shares worth $1.33M. The position accounts for 0.05% of the portfolio, ranked #267.
Csenge Advisory Group first reported a position in TMO in Q3 2017 and has held it in 30 quarters since. The position peaked at $2.27M in Q3 2024. 2,620 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Csenge Advisory Group held 2,646 shares of Thermo Fisher Scientific worth $1.33M as of Q2 2026.
- Csenge Advisory Group sold 41 Thermo Fisher Scientific shares in Q2 2026, an estimated $19.7K.
- Thermo Fisher Scientific made up 0.05% of Csenge Advisory Group's portfolio in Q2 2026, its #267 holding.
- Csenge Advisory Group first reported a position in Thermo Fisher Scientific in Q3 2017 and has held it in 30 quarters since.
- Csenge Advisory Group's Thermo Fisher Scientific position peaked at $2.27M in Q3 2024.
- 2,620 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Csenge Advisory Group's 13F filing for Q2 2026, filed 10 Aug 2026.